Literature DB >> 28892562

Triggering immunological memory against the tapeworm Hymenolepis diminuta to protect against colitis.

A Wang1, T Arai1, A Campbell1, J L Reyes2, F Lopes1, D M McKay1.   

Abstract

Infection with parasitic helminths can ameliorate the severity of concomitant inflammatory disease. To use the tapeworm, Hymenolepis diminuta, and to extend this concept by assessing whether triggering a memory response against the worm inhibits dinitrobenzene sulphonic acid (DNBS)-induced colitis in Balb/c mice. Initial studies revealed that oral infection with 1, 3 or 5 H. diminuta cysticercoids 8 days before intrarectal administration of DNBS (3 mg) resulted in less severe inflammation and that infected mice displayed an increased propensity for T helper-2 immunity. A 1 mg dose of a PBS-soluble extract of the worm (HdAg) delivered intraperitoneally concomitant with DNBS was anticolitic as determined by macroscopic and histological disease scores 72 hour post-DNBS. Mice infected 28 days previously had a memory response as determined by HdAg-evoked increases in interleukin (IL)-4 and IL-10 from in vitro stimulated splenocytes and serum anti-H. diminuta IgG. Moreover, mice infected with 5 H. diminuta 28 days previously were protected from DNBS-induced colitis by secondary infection or 100 μg HdAg (ip.) at the time of DNBS treatment. An additional approach to managing inflammatory disease could be infection with H. diminuta followed by eliciting antiworm recall responses.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Hymenolepis diminutazzm321990; cestode; colon; dinitrobenzene sulphonic acid; intestine

Mesh:

Substances:

Year:  2017        PMID: 28892562     DOI: 10.1111/pim.12490

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  2 in total

1.  Production and Use of Hymenolepis diminuta Cysticercoids as Anti-Inflammatory Therapeutics.

Authors:  Kendra Smyth; Claire Morton; Amanda Mathew; Sahil Karuturi; Cliff Haley; Min Zhang; Zoie E Holzknecht; Chelsea Swanson; Shu S Lin; William Parker
Journal:  J Clin Med       Date:  2017-10-24       Impact factor: 4.241

2.  Hymenolepis diminuta-based helminth therapy in C3(1)-TAg mice does not alter breast tumor onset or progression.

Authors:  Scott Sauer; Dylan Beinart; Sade M B Finn; Sereena L Kumar; Qing Cheng; Shelley E Hwang; William Parker; Gayathri R Devi
Journal:  Evol Med Public Health       Date:  2021-02-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.